

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Encapsulation of *Lactobacillus rhamnosus* probiotic bacteria by electrospinning method using poly di actelene polymer.

Protocol summary

Study aim

Investigating the effect of *Lactobacillus rhamnosus* probiotic on constipation.

Design

Randomized clinical trial with control group-placebo and double-blind with two parallel groups. Study phase: 3 block randomization. Expected sample size: 50 people, 25 people in the intervention group and 25 people in the control group.

Settings and conduct

The samples will be selected from among those who visit the gastroenterology clinic of Hazrat Masoumeh (former Khorrami) and Shahid Beheshti hospitals in Qom. Product packaging will be coded by the company in two ways. The codes are kept secret by the company from the patients and researchers and will be announced to the researchers after the completion of the clinical trial by the company.

Participants/Inclusion and exclusion criteria

Entry conditions: people who are 18 years old and above, people who are diagnosed with moderate and mild constipation based on the Rome criteria, people who consent to participate in the study. Exit conditions: lack of mobility and drug addiction activity. A known metabolic disorder (diabetes) Taking a special drug that interferes with these drugs Taking a drug to treat neurological and mental disorders Not taking the drug according to the schedule (if the drug is not taken 4 times a week) Receiving treatment for constipation in the previous 2 weeks from entering the study, symptoms of acute gastroenteritis such as: nausea, vomiting and diarrhea during the study.

Intervention groups

Intervention group: Patients will consume Familact® probiotic capsules. Control group: patients will take placebo capsules.

Main outcome variables

1. Severity of abdominal pain 2. The degree of discomfort or heaviness in the abdomen 3. The degree of

bloating or abdominal swelling 4. Heartburn

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230105057061N1**

Registration date: **2023-08-22, 1402/05/31**

Registration timing: **retrospective**

Last update: **2023-08-22, 1402/05/31**

Update count: **0**

Registration date

2023-08-22, 1402/05/31

Registrant information

Name

Esmaeel Qashamzadeh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 25 3288 6211

Email address

qashamzadeh1399@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-05-02, 1402/02/12

Expected recruitment end date

2023-06-02, 1402/03/12

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Encapsulation of Lactobacillus rhamnosus probiotic bacteria by electrospinning method using poly diacetylene polymer.

Public title

Encapsulation of Lactobacillus rhamnosus bacteria

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

The main conditions for entering the study before randomization: patients will be selected based on the Rome II criteria according to the diagnosis of digestive and liver diseases; (Rome II criteria: abdominal pain or any digestive discomfort for at least 3 months during a year) The past three months can be consecutive or non-consecutive, along with two of the following three: resolution of pain with defecation, onset of symptoms with change in frequency of defecation, onset of symptoms with change in stool shape) minimum age 18 years of informed consent of the patient, which is adopted in writing after providing all the necessary explanations for them.

Exclusion criteria:

The main conditions of non-entry into the study before randomization: a history of major gastrointestinal surgery, chronic use of antibiotics, corticosteroids, and immunosuppressive drugs, regular use of drugs that change the movements of the digestive system, such as metoclopramide, cisapride, domperidone, narcotics, especially Opioid derivatives, laxative agents, antidiarrheal agents, and other drugs effective in the treatment of IBS, which are described in more detail in the text. The presence of severe mental and behavioral disorders in the patient, the presence of food allergies, the presence of any organic intestinal disease or chronic digestive disease

Age

From **9 years** old to **80 years** old

Gender

Male

Phase

0

Groups that have been masked

- Participant
- Care provider
- Investigator

Sample size

Target sample size: **25**

Randomization (investigator's opinion)

Randomized

Randomization description

In this clinical trial study, the sample size is estimated to be 50 people, and finally 25 people will be in the intervention group and 25 people will be in the control group. The samples will be selected from among those who visit the gastroenterology clinic of Khorrani (Hazrat Masoumeh) and Shahid Beheshti Hospitals in Qom.

Product packaging will be coded by the company in two ways. Each of the two randomly divided groups will receive a type of drug code. The codes are kept secret by the company from the patients and researchers and will be announced to the researchers at the end of the study after the completion of the clinical trial by the company.

Blinding (investigator's opinion)

Double blinded

Blinding description

The upcoming clinical trial will be conducted in a randomized, double-blind, placebo-control group. In this clinical trial study, the sample size is estimated to be 50 people, and finally 25 people will be in the intervention group and 25 people will be in the control group. Blocked randomization method is considered for this study. In this way, the first qualified patient enters group A and the second one enters group B, and in the same way, the rest of the patients are divided between the two groups one after the other.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Islamic Azad University Qom branch

Street address

Islamic Azad University, Qom branch, 15 Khordad Blvd.

City

Qom

Province

Ghous

Postal code

3714963744

Approval date

2023-04-11, 1402/01/22

Ethics committee reference number

IR.IAU.Qom.REC.1402.021

Health conditions studied

1

Description of health condition studied

Constipation and gastrointestinal cancer

ICD-10 code

C26.9

ICD-10 code description

Gastrointestinal tract NOS

Primary outcomes

1

Description

Abdominal pain intensity

Timepoint

At the beginning of the study (before the start of the intervention) and at the end of the study (the end of the intervention) during the intervention and 3 months after the intervention

Method of measurement

Questionnaire (numbers 0 to 10 to check pain intensity, where 0 represents the absence of pain and 10 represents very intense pain)

2

Description

Timepoint

Method of measurement

Secondary outcomes

1

Description

Albumin and pre-albumin

Timepoint

Before the intervention, during the intervention and 3 months after the intervention

Method of measurement

Laboratory kits

2

Description

Alkaline phosphatase

Timepoint

Before the intervention, during the intervention and 3 months after the intervention

Method of measurement

Laboratory kits

3

Description

Alanine aminotransferase

Timepoint

Before the intervention, during the intervention and 3 months after the intervention

Method of measurement

Laboratory kits

4

Description

Erythrocyte sedimentation rate (ESR)

Timepoint

Before the intervention, during the intervention and 3 months after the intervention

Method of measurement

Laboratory kits

Intervention groups

1

Description

Control group: patients for 30 consecutive days, daily two 500 mg capsules of placebo containing an ineffective substance with the same shape and appearance and packaging as the original drug and unrecognizable to patients and researchers by the company (Danish Biopharmaceutical Company, (Tehran) designed and produced will consume. Since it is indistinguishable from the original drug, it is recommended to take it at the same time as the original drug, between each meal.

Category

Placebo

2

Description

Control group: use of dietary supplements Figilax and Fitolax as well as folic acid and zinc in a period of 90 days

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Beheshti Hospital, Qom

Full name of responsible person

Dr. Seyed Saeed Sarkashikian

Street address

Shahid Beheshti Hospital, Shahid Beheshti Street, Qom, Iran

City

Qom

Province

Ghous

Postal code

3719964797

Phone

+98 25 3770 8001

Email

qashamzadeh1399@gmail.com

2

Recruitment center

Name of recruitment center

Hazrat Masoumeh Hospital, Qom

Full name of responsible person

Gholam Ali Jafari

Street address

Hospital, Imam Khomeini Street, after Shahid Zain al-Din Square, next to Imam Hassan Mosque,

City

Qom

Province

Ghoum
Postal code
3719815539
Phone
+98 25 3669 2004
Email
qashamzadeh1399@outlook.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Islamic Azad University
Full name of responsible person
Mahbouba Al Sadat Sharif
Street address
15 Khordad Blve, Islamic Azad University, Qom branch
City
Qom
Province
Ghoum
Postal code
3749113191
Phone
+98 25 3280 8080
Email
info@qom-iau.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Islamic Azad University
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Islamic Azad University
Full name of responsible person
Islamic Azad University
Position
Member of the academic staff of Islamic Azad University, Qom branch
Latest degree
Ph.D.
Other areas of specialty/work

Nuclear Medicine
Street address
Pardisan St, Islamic Azad University, Qom branch
City
Qom
Province
Ghoum
Postal code
3749113191
Phone
+98 25 3280 8080
Email
qom@cms.iau.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Islamic Azad University
Full name of responsible person
Dr. Mohammad Dakhili Ranj Jo
Position
Assistant Professor
Latest degree
Medical doctor
Other areas of specialty/work
Mycology
Street address
Pardisan Blvd, Islamic Azad University, Qom branch
City
Qom
Province
Ghoum
Postal code
3749113191
Phone
+98 25 3280 8080
Email
dr_dakhili@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Islamic Azad University
Full name of responsible person
Ismail Qeshmzadeh
Position
Student
Latest degree
Bachelor
Other areas of specialty/work
Microbiology
Street address
Pardisan Blvd, Islamic Azad University, Qom branch
City
Qom
Province
Ghoum
Postal code
3749113191

Phone

+98 25 3280 8080

Email

qashamzadeh1399@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to

make this available

Title and more details about the data/document

SPSS file data by de-identifying individual characteristics after The completion and printing of this study will be available to the applicant researchers took

When the data will become available and for how long

The access period starts after the results are printed

To whom data/document is available

Both researchers and related industries

Under which criteria data/document could be used

Any kind of scientific, practical and research use with awareness and acquisition Consent from researchers is allowed.

From where data/document is obtainable

Refer to the researchers of the project, e-mail: qashamzadeh1399@gmail.com

What processes are involved for a request to access data/document

While sending the request by email, complete identification information including name and Surname and membership number in a scientific, research or industrial authority and Provide a full explanation of the type of data use and its purposes to do

Comments